Engineered T-cell Therapeutics (therapeutic TCRs)2021-02-12T00:28:25+00:00

Project Description

Families of T-cell receptors have been sequenced and characterized corresponding to share neoantigens to common mutations found in many cancers. These TCR families correspond to HLA sub-types frequented in upwards of 60-80% of the population. Using advanced gene editing technology, the patient’s own T-cells are redirected to targeted neoantigens expressed by the patient’s tumor.